Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.
Short latency afferent inhibition in Parkinson's disease patients with dementia†
Article first published online: 17 MAY 2012
Copyright © 2012 Movement Disorder Society
Volume 27, Issue 8, pages 1052–1055, July 2012
How to Cite
Celebi, O., Temuçin, Ç. M., Elibol, B. and Saka, E. (2012), Short latency afferent inhibition in Parkinson's disease patients with dementia. Mov. Disord., 27: 1052–1055. doi: 10.1002/mds.25040
- Issue published online: 17 JUL 2012
- Article first published online: 17 MAY 2012
- Manuscript Accepted: 12 APR 2012
- Manuscript Revised: 11 APR 2012
- Manuscript Received: 18 OCT 2011
- Parkinson's disease;
- Alzheimer's disease;
- Parkinson's disease dementia
Cortical cholinergic deficiency occurs in Parkinson's disease (PD) and is more severe in PD dementia (PDD). Short-latency afferent inhibition (SAI) can be used as an in vivo test for the evaluation of the cholinergic circuit in the cerebral motor cortex.
SAI and neuropsychological profile were studied in nondemented PD, PDD, Alzheimer's disease (AD) patients, and age-matched controls.
SAI was significantly impaired in AD cases (94.7 ± 6.2 versus 55.5 ± 4.0; P < 0.0001). In PD patients, it was not different from controls (61.4 ± 5.8 versus 55.5 ± 4.0; P = 0.412). PDD cases demonstrated a significant impairment in SAI (91.4 ± 5.2 versus 55.5 ± 4.0; P < 0.0001). A high correlation was found between SAI and Mini–Mental State Examination (r = −0.68; P < 0.0001).
These findings add further evidence that differential cholinergic deficiency occurs in PD and PDD. SAI can be a neurophysiological correlate of PDD. © 2012 Movement Disorder Society